The Administrative Core (Core A), headed by the Program Director Dr. Rabinovitch, will oversee the interactions between the Leaders of the Projects and Core B, the Advanced Proteomic Phenotyping Core (APP). The Core will organize monthly two-hour TPPG meetings of the program participants, i.e., project leaders, collaborators and consultants, biostatisticians, postdoctoral fellows, research associates and nurse coordinators. Each week, one of the Projects or Core Leaders will be responsible for the scientific agenda. The Administrative Core will present any regulatory or procedural issues in the last half hour. The Core will also organize a bi-annual meeting with the Internal Advisory Board and an annual meeting with the External Advisory Board. The Core will coordinate educational activities of the trainees, including facilitation of trainee's access to relevant resources offered by training programs (K12, T32) and the Office of Postdoctoral Affairs at Stanford. The Administrative Core will work closely with Project 3 leader, Dr. Zamanian, and the Data Coordinating Center to help organize the Phase I and II clinical trials, including coordination of meetings with the other site directors for the Phase II clinical trial, and communication with the DSMB, the Medical Monitors and Program Managers. The Core will act as liaison between the project leaders and Proteo (our commercial partner and IND Sponsor) and between the Project 3 Leader and SRI international, regarding the 180 day GLP study in the rats and the pharmacokinetic and immunogenicity studies in the Phase I and II clinical trials. The Core will also facilitate interaction with the NIH SMARTT program, for regulatory help in filing the IND and in preparing for the fast track meeting with the FDA prior to initiating the Phase II clinical trial. The Administrative Core will also act as liaison between the Project Leaders, Proteo and the FDA. The Core will assist with preparation and updating of animal and clinical protocols, and with obtaining IRB approvals. The Core will facilitate the preparation of publications, presentations and progress reports.

Public Health Relevance

The Administrative Core (Core A) will oversee the interactions between the Leaders of the Projects and Core B, the Advanced Proteomic Phenotyping Core (APP), and act as liaison with our external partners, the NIH, the FDA, and SRI, a company often contracted by NIH, that will carry out preclinical studies in the rats, and pharmacokinetic and immunogenicity studies for the Phase I and II clinical trials. The Core will also coordinate meetings and conference calls with our commercial partner, Proteo. and with the Internal and External Advisory Boards. The Core will coordinate educational activities of the trainees, and assist with updating of animal and clinical protocols, and will facilitate the preparation of publications, presentations and progress reports.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL108797-08
Application #
9734134
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Xiao, Lei
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
8
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Hsu, Joe L; Manouvakhova, Olga V; Clemons, Karl V et al. (2018) Microhemorrhage-associated tissue iron enhances the risk for Aspergillus fumigatus invasion in a mouse model of airway transplantation. Sci Transl Med 10:
Alejandre Alcazar, Miguel A; Kaschwich, Mark; Ertsey, Robert et al. (2018) Elafin Treatment Rescues EGFR-Klf4 Signaling and Lung Cell Survival in Ventilated Newborn Mice. Am J Respir Cell Mol Biol 59:623-634
Lin, Y-C; Sung, Y K; Jiang, X et al. (2017) Simultaneously Targeting Myofibroblast Contractility and Extracellular Matrix Cross-Linking as a Therapeutic Concept in Airway Fibrosis. Am J Transplant 17:1229-1241
Saito, Toshie; Miyagawa, Kazuya; Chen, Shih-Yu et al. (2017) Upregulation of Human Endogenous Retrovirus-K Is Linked to Immunity and Inflammation in Pulmonary Arterial Hypertension. Circulation 136:1920-1935
Lama, Vibha N; Belperio, John A; Christie, Jason D et al. (2017) Models of Lung Transplant Research: a consensus statement from the National Heart, Lung, and Blood Institute workshop. JCI Insight 2:
Maron, Bradley A; Hess, Edward; Maddox, Thomas M et al. (2016) Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circulation 133:1240-8
Nicolls, Mark R; Hsu, Joe L; Jiang, Xinguo (2016) Microvascular injury after lung transplantation. Curr Opin Organ Transplant 21:279-84
Milla, Carlos E; Moss, Richard B (2015) Recent advances in cystic fibrosis. Curr Opin Pediatr 27:317-24
Hilgendorff, Anne; Parai, Kakoli; Ertsey, Robert et al. (2015) Lung matrix and vascular remodeling in mechanically ventilated elastin haploinsufficient newborn mice. Am J Physiol Lung Cell Mol Physiol 308:L464-78
Nickel, Nils P; Spiekerkoetter, Edda; Gu, Mingxia et al. (2015) Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling. Am J Respir Crit Care Med 191:1273-86

Showing the most recent 10 out of 50 publications